We assessed the value of fusion (18)F-fluoromethylcholine ((18)F-choline) Positron Emission To-mography / Magnetic Resonance Imaging (PET/MRI) for image-guided (targeted) prostate biop-sies to detect significant prostate cancer (Gleason ≥ 3+4) compared to standard (systematic 12-core) biopsies.
We evaluated the ability to detect clinically significant prostate cancer (CS-PCa) using a novel electromagnetically (EM) tracked transperineal MR/US fusion guided targeted biopsy (tpTBx) platform and the impact of inter-reader variability on cancer detection.
To evaluate the accuracy of multiparametric magnetic resonance-transrectal ultrasound fusion targeted biopsy (TBx) in the characterization of the index tumor, as confirmed by association with radical prostatectomy (RP) specimens.
Multiparametric magnetic resonance imaging (mpMRI) has improved clinicians' ability to detect clinically significant prostate cancer (csPCa). Combining or fusing these images with the real-time imaging of transrectal ultrasound (TRUS) allows urologists to better sample lesions with a targeted biopsy (Tbx) leading to the detection of greater rates of csPCa and decreased rates of low-risk PCa.
Lessons learned during a 6-year experience with more than 1200 patients undergoing targeted prostate biopsy via MRI/US fusion are reported:
Magnetic resonance imaging/ultrasound-guided fusion biopsy (FBx) is more accurate at detecting clinically significant prostate cancer than conventional transrectal ultrasound-guided systematic biopsy.
To compare transperineal (TP-TBx) and transrectal (TR-TBx) targeted prostate biopsy in a prospective non randomized single surgeon series of MR/US fusion-guided targeted biopsy performed using an electromagnetic tracking platform (NCT04026763).
Login to update email address, newsletter preferences and use bookmarks.